BioSpace News Archive

Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products.

Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.

Revolution Medicines, Inc. today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference being held on October 7-10, 2021.

InMed Pharmaceuticals Inc. today announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”).

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia.

Dr. Stuart Kornfeld, M6P Therapeutics’ Co-Founder, to Receive the Roscoe O. Brady Award For Innovation and Accomplishment at WORLD Symposium ™ 2022

Hemanext Inc today announced that it has successfully closed its Series A fundraising round, raising $15m from both existing and new investors.

BioDelivery Sciences International, Inc., a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced it will host a virtual ELYXYB™ Investor Day on Thursday, October 14, 2021, at 10:30am ET.

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced that it has entered into a revenue interest financing agreement with HealthCare Royalty Partners® for up to $125 million.

AMO Pharma Limited today announced that the first patient has completed participation in the REACH-CDM pivotal clinical trial and has been enrolled in the REACH-CDM X study